At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 82 enrolled
Drug / intervention
Pembrolizumabdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2 Study of Pembrolizumab (MK-3475) After Autologous Stem Cell Transplantation in Patients With Relapsed/Refractory Classical Hodgkin Lymphoma and, Diffuse Large B Cell Lymphoma and T- Cell Non-Hodgkin Lymphoma
In Brief
A Phase 2 clinical trial evaluating Pembrolizumab for Hodgkin Lymphoma and 2 related conditions. Completed, enrolled 82 participants across 6 sites.
Detailed Summary
This phase II study is designed to determine the clinical efficacy of PD-1 blockade, using the anti-PD-1 monoclonal antibody pembrolizumab (MK-3475), administered as consolidation therapy after autologous stem cell transplant (ASCT), in patients with relapsed or refractory (R/R) Diffuse Large B Cell Lymphoma (DLBCL), classical Hodgkin Lymphoma (cHL) or peripheral T-cell lymphoma (PTCL) in 1st remission.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
CollaboratorsMerck Sharp & Dohme LLC
Timeline
Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
First PostedFeb 2015
Enrollment StartApr 2015
Primary CompletionOct 2021
Study CompletionJun 2023
TodayJul 2026
First PostedFeb 13, 2015
Enrollment StartApr 1, 2015
Primary CompletionOct 26, 2021
Study CompletionJun 1, 2023
TodayJul 2, 2026
Enrollment to primary: 6.6 yearsPosted 11.4 years ago
Interventions
Pembrolizumabdrug
Anti-PD-1 monoclonal antibody